BoneSupport - Public Comps and Valuation Multiples

BoneSupport Overview

About BoneSupport

Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and has the ability to release pharmaceuticals to promote healing. Its products focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: North America (NA) and Europe & Rest of the World (EUROW).

Founded

1999

HQ

Employees

Website

bonesupport.com

Sectors

Medical Devices
Drug Development & Therapeutics
DeepTech
HealthTech
BioTech

Financials

LTM Revenue $100M

LTM EBITDA $21.4M

EV

$2.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BoneSupport Financials

BoneSupport has a last 12-month revenue of $100M and a last 12-month EBITDA of $21.4M.

In the most recent fiscal year, BoneSupport achieved revenue of $89.2M and an EBITDA of $17.2M.

BoneSupport expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BoneSupport valuation multiples based on analyst estimates

BoneSupport P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$58.7M	$89.2M	XXX	XXX	XXX
Gross Profit	$29.6M	$53.7M	XXX	XXX	XXX
Gross Margin	50%	60%	XXX	XXX	XXX
EBITDA	$2.9M	$17.2M	XXX	XXX	XXX
EBITDA Margin	5%	19%	XXX	XXX	XXX
Net Profit	-$6.8M	$24.3M	XXX	XXX	XXX
Net Margin	-12%	27%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

BoneSupport Stock Performance

As of April 15, 2025, BoneSupport's stock price is SEK 309 (or $31).

BoneSupport has current market cap of SEK 20.4B (or $2.0B), and EV of SEK 20.2B (or $2.0B).

See BoneSupport trading valuation data

BoneSupport Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.0B	$2.0B	XXX	XXX	XXX	XXX	$0.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

BoneSupport Valuation Multiples

As of April 15, 2025, BoneSupport has market cap of $2.0B and EV of $2.0B.

BoneSupport's trades at 19.9x LTM EV/Revenue multiple, and 93.5x LTM EBITDA.

Analysts estimate BoneSupport's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for BoneSupport and 10K+ public comps

BoneSupport Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$2.0B	XXX	XXX	XXX
EV/Revenue	22.4x	XXX	XXX	XXX
EV/EBITDA	116.2x	XXX	XXX	XXX
P/E	152.2x	XXX	XXX	XXX
P/E/Growth	1.7x	XXX	XXX	XXX
EV/FCF	336.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BoneSupport Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

BoneSupport Valuation Multiples

BoneSupport's NTM/LTM revenue growth is 41%

BoneSupport's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, BoneSupport's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate BoneSupport's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for BoneSupport and other 10K+ public comps

BoneSupport Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	52%	XXX	XXX	XXX	XXX
EBITDA Margin	19%	XXX	XXX	XXX	XXX
EBITDA Growth	499%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	60%	XXX	XXX	XXX	XXX
Revenue per Employee	$1.0M	XXX	XXX	XXX	XXX
Opex per Employee	$0.7M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	57%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	11%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	8%	XXX	XXX	XXX	XXX
Opex to Revenue	74%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry